Jeffrey L. Nordstrom

Medicine · Health Sciences

33h-index4.9kcitations102works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(29), CAR-T cell therapy research(21), RNA Interference and Gene Delivery(19), Immunotherapy and Immune Responses(18), Virus-based gene therapy research(16)

Publications102 total

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules
UNC Libraries·2024Open Access
Margetuximab in HER2-positive metastatic breast cancer
Future Oncology·2023· 15 citedOpen Access
Supplemental Figure S2 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Tables S1 and S2 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S5 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S1 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S6 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Data from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure Legends from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Data from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S5 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S6 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S1 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure Legends from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S2 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S3 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S3 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S4 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Figure S4 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
Supplemental Tables S1 and S2 from MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Scott Koenig(11), Syd Johnson(10), Bert W. O’Malley(8), Paul A. Moore(8), Ezio Bonvini(7), Ming‐Jer Tsai(5), Liqin Liu(5), Chia‐Ying K. Lam(5), David M. Margolis(5), Guido Ferrari(5), Sergey Gorlatov(4), Yinhua Yang(4), Jonathan J. Mitschelen(3), Hope S. Rugo(3), Edwin P. Rock(3), William J. Gradishar(3), Dennis R. Roop(3), Steve Burke(3), Hua Li(3), Valentina Ciccarone(3)